These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 12714021)
1. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021 [TBL] [Abstract][Full Text] [Related]
2. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Wallentin L; Dellborg DM; Lindahl B; Nilsson T; Pehrsson K; Swahn E Clin Cardiol; 2001 Mar; 24(3 Suppl):I12-4. PubMed ID: 11286309 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146 [TBL] [Abstract][Full Text] [Related]
4. Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. Kim W; Jeong MH; Hwang SH; Kim KH; Hong YJ; Ahn YK; Kim W; Cho JG; Park JC; Kang JC Int Heart J; 2006 Nov; 47(6):821-31. PubMed ID: 17268117 [TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317 [TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K; Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769 [TBL] [Abstract][Full Text] [Related]
7. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418 [TBL] [Abstract][Full Text] [Related]
8. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995 [TBL] [Abstract][Full Text] [Related]
9. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800 [TBL] [Abstract][Full Text] [Related]
10. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040 [TBL] [Abstract][Full Text] [Related]
11. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569 [TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). Frostfeldt G; Ahlberg G; Gustafsson G; Helmius G; Lindahl B; Nygren A; Siegbahn A; Swahn E; Venge P; Wallentin L J Am Coll Cardiol; 1999 Mar; 33(3):627-33. PubMed ID: 10080461 [TBL] [Abstract][Full Text] [Related]
13. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799 [TBL] [Abstract][Full Text] [Related]
14. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Malcolm AD; Keltai M; Walsh MJ Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909 [TBL] [Abstract][Full Text] [Related]
15. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Antman EM; Giugliano RP; Gibson CM; McCabe CH; Coussement P; Kleiman NS; Vahanian A; Adgey AA; Menown I; Rupprecht HJ; Van der Wieken R; Ducas J; Scherer J; Anderson K; Van de Werf F; Braunwald E Circulation; 1999 Jun; 99(21):2720-32. PubMed ID: 10351964 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346 [TBL] [Abstract][Full Text] [Related]
17. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283 [TBL] [Abstract][Full Text] [Related]
18. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E; Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601 [TBL] [Abstract][Full Text] [Related]
19. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541 [TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature. Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]